Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy

European Urology

Volumn 69, Issue 1, 2016, Pages 84-91

  Gershman, Boris ^a   Moreira, Daniel M ^a   Boorjian, Stephen A ^a   Lohse, Christine M ^a   Cheville, John C ^a   Costello, Brian A ^a   Leibovich, Bradley C ^a   Thompson, R Houston ^a  

^a MAYO CLINIC   (United States)

Author keywords

Complications; Cytoreductive nephrectomy; Prolonged hospitalization; Renal cell carcinoma; Systemic therapy

Indexed keywords

ABSCESS; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CYTOREDUCTIVE NEPHRECTOMY; DEEP VEIN THROMBOSIS; DIALYSIS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; KIDNEY CARCINOMA; LAPAROSCOPIC SURGERY; LENGTH OF STAY; LIVER METASTASIS; LUNG EMBOLISM; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; MORBIDITY; NEPHRECTOMY; OUTCOME ASSESSMENT; PARAAORTIC LYMPH NODE; PERIOPERATIVE MORBIDITY; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS; SYSTEMIC THERAPY; THERAPY DELAY; TRANSFUSION; WOUND DEHISCENCE; WOUND INFECTION; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; BLOOD TRANSFUSION; CARCINOMA, RENAL CELL; CYTOREDUCTIVE SURGERY; KIDNEY NEOPLASMS; LAPAROSCOPY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PERIOPERATIVE PERIOD; PEROPERATIVE CARE; RETROPERITONEUM; RETROSPECTIVE STUDY; SECONDARY; TIME TO TREATMENT;

ANTINEOPLASTIC AGENT;

AGED; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HUMANS; INTRAOPERATIVE CARE; KIDNEY NEOPLASMS; LAPAROSCOPY; LENGTH OF STAY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; METASTASECTOMY; MIDDLE AGED; NEPHRECTOMY; PERIOPERATIVE PERIOD; RETROPERITONEAL SPACE; RETROSPECTIVE STUDIES; TIME-TO-TREATMENT;

EID: 84955738356     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.05.022     Document Type: Article

References (28)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 Cancer J Clin 64 2014 9 29
2. C.J. Kane, K. Mallin, J. Ritchey, M.R. Cooperberg, and P.R. Carroll Renal cell cancer stage migration: analysis of the National Cancer Data Base Cancer 113 2008 78 83
3. R.J. Motzer, N. Agarwal, C. Beard, and et al. NCCN clinical practice guidelines in oncology: kidney cancer J Natl Compr Cancer Netw 7 2009 618 630
4. R.C. Flanigan, S.E. Salmon, B.A. Blumenstein, and et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
5. G.H. Mickisch, A. Garin, H. van Poppel, L. de Prijck, and R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
6. T.K. Choueiri, W. Xie, C. Kollmannsberger, and et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy J Urol 185 2011 60 66
7. A.A. Aizer, Y. Urun, R.R. McKay, A.S. Kibel, P.L. Nguyen, and T.K. Choueiri Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC) BJU Int 113 2014 E67 E74
8. Q.D. Trinh, M. Bianchi, J. Hansen, and et al. In-hospital mortality and failure to rescue after cytoreductive nephrectomy Eur Urol 63 2013 1107 1114
9. F. Abdollah, M. Sun, R. Thuret, and et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study Ann Surg Oncol 18 2011 2988 2996
10. M. Sun, F. Abdollah, J. Schmitges, and et al. Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA BJU Int 109 2012 1807 1812
11. J.L. Silberstein, A. Adamy, A.C. Maschino, and et al. Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC) BJU Int 110 2012 1276 1282
12. Jackson B, Fowler S, Williams S. Perioperative outcomes of cytoreductive nephrectomy in the UK in 2012. BJU Int. In press. http://dx.doi.org/10.1111/bju.12890
13. A. Kutikov, R.G. Uzzo, A. Caraway, and et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy BJU Int 106 2010 218 223
14. M.C. Smaldone, E. Handorf, S.P. Kim, and et al. Temporal trends and factors associated with receipt of systemic therapy in patients undergoing cytoreductive nephrectomy: an analysis of the National Cancer Database J Urol 193 2015 11 18
15. R.L. O'Malley, K.A. Brewer, M.H. Hayn, and et al. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology 78 2011 595 600
16. K.R. Yabroff, L. Harlan, J. Stevens, and A. Martin Patterns of care in adults with renal cell carcinoma: findings in a population based sample J Urol 181 2009 2462 2468
17. S.P. Psutka, S.P. Kim, C.P. Gross, and et al. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization Urology 85 2015 442 451
18. C. Jeldres, S. Baillargeon-Gagne, D. Liberman, and et al. A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States Urology 74 2009 837 841
19. C.K. Tsao, A.C. Small, M. Kates, and et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis World J Urol 31 2013 1535 1539
20. J. McKiernan, and C.G. Wood Cytoreductive nephrectomy for metastatic renal cell carcinoma J Urol 190 2013 386 388
21. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
22. C. Terrone, S. Guercio, S. De Luca, and et al. The number of lymph nodes examined and staging accuracy in renal cell carcinoma BJU Int 91 2003 37 40
23. J.H. Blom, H. van Poppel, J.M. Marechal, and et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881 Eur Urol 55 2009 28 34
24. B.F. Chapin, S.E. Delacroix Jr., S.H. Culp, and et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma Eur Urol 60 2011 964 971
25. R.R. McKay, N. Kroeger, W. Xie, and et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy Eur Urol 65 2014 577 584
26. J.C. Rabets, J. Kaouk, A. Fergany, A. Finelli, I.S. Gill, and A.C. Novick Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma Urology 64 2004 930 934
27. B.J. Linder, I. Frank, J.C. Cheville, and et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy Eur Urol 63 2013 839 845
28. T. Takagi, T. Sugihara, H. Yasunaga, and et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based analysis of perioperative outcomes according to clinical stage Int J Urol 21 2014 770 775